



ASX Announcement

6 February 2020

Creso Pharma makes technological breakthrough for expansion of human health product line

Highlights

- Creso Pharma has achieved a key technological milestone, developing its first water-soluble microgranulated hemp plant granules product as an expansion of its cannaQIX® human health product line
- This new technology was developed together with Switzerland's Domaco Pharma and allows hemp oil-free manufacturing of cannaQIX® hemp plant-based gum arabicum lozenges, Creso Pharma's hemp and vitamin-based food supplement
- Creso Pharma produces and markets the cannaQIX® products in collaboration with with commercial partners in different countries

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to announce the achievement of a key technological milestone. The Company has successfully developed and tested its first oil free hemp plant-based gum arabicum lozenges. The technological breakthrough will be used to extend the Company's successful cannaQIX® product line.

Developed over the past nine months, the new technology allows hemp oil free production, bringing the full benefit of the natural hemp plant to the consumers. The product also offers significant regulatory advantages in several countries. The formulation contains hemp compounds which are already approved for use in consumer products, providing the Company with a path to market for food supplement products without the need for regulatory approval.

This new products use natural hemp plant and provide an "entourage effect" in which various compounds work together to strengthen the key benefits such as helping to manage stress and improving well-being.

Creso Pharma plans to distribute the new products globally with different commercial partners in several countries and expects that the products will be ready for launch in Q3 2020.



Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma said: “We are proud of having successfully developed this innovative oil free hemp plant based technology. The new products contain hemp compounds which are already approved for use in consumer products. Importantly, this means that we have an additional path to market for our hemp-based food supplements without the need for regulatory approval, thus increasing our commercial options and expanding the potential territories we can sell the products in.”

Dr. Gian Trepp, R&D/Commercial Director of Creso Pharma said: “With the achievement of this innovation of the oil free hemp based technology Creso successfully addresses the regulatory and market access challenges enabling us to enter additional markets on a global basis.”

Ends

Authority and Contact Details

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network
E: julia@thecapitalnetwork.com.au
P: +61 419 815 386

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com



About Virbac

Virbac offers veterinarians, farmers and pet owners in more than 100 countries a practical range of products and services to diagnose, prevent and treat the majority of pathologies, while improving the animals' quality of life. With these innovative solutions covering more than 50 species, Virbac contributes, day after day, to shape the future of animal health. To learn more, please visit: www.virbac.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations.

The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.